DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback